Humana Inc (HUM) Expected to Announce Earnings of $2.54 Per Share

Equities research analysts predict that Humana Inc (NYSE:HUM) will report $2.54 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Humana’s earnings, with the lowest EPS estimate coming in at $2.49 and the highest estimate coming in at $2.60. Humana posted earnings per share of $2.06 during the same quarter last year, which indicates a positive year over year growth rate of 23.3%. The business is expected to issue its next earnings results on Wednesday, February 6th.

On average, analysts expect that Humana will report full year earnings of $14.44 per share for the current financial year, with EPS estimates ranging from $14.40 to $14.50. For the next financial year, analysts anticipate that the company will post earnings of $17.50 per share, with EPS estimates ranging from $17.15 to $18.25. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that cover Humana.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, November 7th. The insurance provider reported $4.58 earnings per share for the quarter, topping the Zacks’ consensus estimate of $4.29 by $0.29. The business had revenue of $14.21 billion for the quarter, compared to analysts’ expectations of $13.97 billion. Humana had a net margin of 2.70% and a return on equity of 19.10%. During the same quarter in the prior year, the company earned $3.39 earnings per share.

A number of equities research analysts have weighed in on the stock. MED upped their price objective on shares of Humana from $350.00 to $373.00 and gave the stock an “outperform” rating in a report on Thursday, November 8th. Piper Jaffray Companies increased their price target on shares of Humana from $355.00 to $380.00 and gave the company an “overweight” rating in a report on Friday, August 24th. SunTrust Banks increased their price target on shares of Humana to $380.00 and gave the company a “hold” rating in a report on Wednesday, September 19th. Jefferies Financial Group increased their price target on shares of Humana from $388.00 to $410.00 and gave the company a “buy” rating in a report on Thursday, November 8th. Finally, Zacks Investment Research cut shares of Humana from a “buy” rating to a “hold” rating in a report on Wednesday, August 8th. Seven equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Humana presently has an average rating of “Buy” and an average price target of $352.30.

Shares of HUM opened at $329.47 on Friday. The stock has a market capitalization of $45.31 billion, a price-to-earnings ratio of 28.14, a price-to-earnings-growth ratio of 1.57 and a beta of 1.03. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.68 and a current ratio of 1.68. Humana has a fifty-two week low of $242.00 and a fifty-two week high of $355.88.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 25th. Investors of record on Monday, December 31st will be given a dividend of $0.50 per share. The ex-dividend date is Friday, December 28th. This represents a $2.00 dividend on an annualized basis and a yield of 0.61%. Humana’s dividend payout ratio (DPR) is 11.96%.

In related news, CEO Bruce D. Broussard sold 18,000 shares of the stock in a transaction that occurred on Monday, September 10th. The shares were sold at an average price of $328.66, for a total transaction of $5,915,880.00. Following the transaction, the chief executive officer now owns 71,085 shares in the company, valued at $23,362,796.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Roy A. Beveridge sold 4,622 shares of the stock in a transaction that occurred on Thursday, November 8th. The shares were sold at an average price of $341.06, for a total transaction of $1,576,379.32. Following the transaction, the insider now owns 10,621 shares in the company, valued at approximately $3,622,398.26. The disclosure for this sale can be found here. 0.60% of the stock is owned by corporate insiders.

Institutional investors have recently modified their holdings of the stock. Honkamp Krueger Financial Services Inc. bought a new position in Humana during the third quarter valued at approximately $108,000. Stratos Wealth Partners LTD. bought a new position in Humana during the third quarter valued at approximately $108,000. Sun Life Financial INC lifted its position in Humana by 120.7% during the second quarter. Sun Life Financial INC now owns 373 shares of the insurance provider’s stock valued at $111,000 after purchasing an additional 204 shares during the period. Migdal Insurance & Financial Holdings Ltd. lifted its position in Humana by 2,984.6% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 401 shares of the insurance provider’s stock valued at $119,000 after purchasing an additional 388 shares during the period. Finally, Smithfield Trust Co. lifted its position in Humana by 531.2% during the third quarter. Smithfield Trust Co. now owns 486 shares of the insurance provider’s stock valued at $165,000 after purchasing an additional 409 shares during the period. Institutional investors own 93.05% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

Recommended Story: Trading Penny Stocks

Get a free copy of the Zacks research report on Humana (HUM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit